Insider Trading Alert - BLL, PCRX And TIBX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 7, 2014, 153 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $776.50 to $183,196,515.00.

Highlighted Stocks Traded by Insiders:

Ball (BLL) - FREE Research Report

Barker Shawn M, who is Vice President & Controller at Ball, sold 6,000 shares at $56.41 on May 7, 2014. Following this transaction, the Vice President & Controller owned 7,804 shares meaning that the stake was reduced by 43.47% with the 6,000-share transaction.

The shares most recently traded at $57.93, up $1.52, or 2.62% since the insider transaction. Historical insider transactions for Ball go as follows:

  • 4-Week # shares sold: 4,679
  • 12-Week # shares sold: 4,679
  • 24-Week # shares sold: 14,679

The average volume for Ball has been 1.0 million shares per day over the past 30 days. Ball has a market cap of $7.9 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 12% year-to-date as of the close of trading on Wednesday.

Ball Corporation, together with its subsidiaries, supplies metal packaging products to the beverage, food, personal care, and household products industries worldwide. The stock currently has a dividend yield of 0.92%. The company has a P/E ratio of 19.5. Currently, there are 3 analysts who rate Ball a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BLL - FREE

TheStreet Quant Ratings rates Ball as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Ball Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Pacira Pharmaceuticals (PCRX) - FREE Research Report

Wicki Andreas, who is Director at Pacira Pharmaceuticals, sold 44,780 shares at $75.78 on May 7, 2014. Following this transaction, the Director owned 1.6 million shares meaning that the stake was reduced by 2.69% with the 44,780-share transaction.

The shares most recently traded at $75.40, down $0.38, or 0.5% since the insider transaction. Historical insider transactions for Pacira Pharmaceuticals go as follows:

  • 12-Week # shares bought: 1,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 22,746

The average volume for Pacira Pharmaceuticals has been 542,200 shares per day over the past 30 days. Pacira Pharmaceuticals has a market cap of $2.6 billion and is part of the health care sector and drugs industry. Shares are up 29.85% year-to-date as of the close of trading on Wednesday.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products primarily for use in hospitals and ambulatory surgery centers worldwide. Currently, there are 7 analysts who rate Pacira Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PCRX - FREE

TheStreet Quant Ratings rates Pacira Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and disappointing return on equity. Get the full Pacira Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TIBCO Software (TIBX) - FREE Research Report

Job Peter J, who is Director at TIBCO Software, sold 1,103 shares at $18.87 on May 7, 2014. Following this transaction, the Director owned 208,007 shares meaning that the stake was reduced by 0.53% with the 1,103-share transaction.

The shares most recently traded at $19.30, up $0.43, or 2.22% since the insider transaction. Historical insider transactions for TIBCO Software go as follows:

  • 4-Week # shares sold: 14,044
  • 12-Week # shares sold: 70,692
  • 24-Week # shares sold: 99,208

The average volume for TIBCO Software has been 2.5 million shares per day over the past 30 days. TIBCO Software has a market cap of $3.1 billion and is part of the technology sector and computer software & services industry. Shares are down 15.35% year-to-date as of the close of trading on Wednesday.

TIBCO Software Inc. provides infrastructure and business intelligence software worldwide. The company offers products in the areas of integration and core infrastructure; business optimization; and process automation and collaboration. The company has a P/E ratio of 37.7. Currently, there are 7 analysts who rate TIBCO Software a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TIBX - FREE

TheStreet Quant Ratings rates TIBCO Software as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full TIBCO Software Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing